
AI is about to change healthcare. These 26 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
To own Proto Labs today, you have to believe in its digital manufacturing platform as a scalable, higher-margin way to serve complex CNC, sheet metal and medical customers, while accepting that growth is not hyper-fast and the stock already trades at a rich earnings multiple. The latest record 2025 results, margin improvement and upbeat 2026 guidance reinforce the near term catalyst around operational execution and demand for CNC and medical-focused services, which the market has quickly rewarded with a sharp share price move. The new acquisition push adds a fresh, potentially material catalyst, but it also introduces integration and capital allocation risk on top of already high expectations and a history of weaker multi‑year earnings. If deals disappoint, the current premium could be harder to justify.
However, investors should be aware that disciplined acquisitions can still carry real integration and valuation risks. Proto Labs' shares are on the way up, but could they be overextended? Uncover how much higher they are than fair value.Explore 2 other fair value estimates on Proto Labs - why the stock might be worth 38% less than the current price!
Disagree with this assessment? Create your own narrative in under 3 minutes - extraordinary investment returns rarely come from following the herd.
These stocks are moving-our analysis flagged them today. Act fast before the price catches up:
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com